Background: Colorectal cancer (CRC) is the third most commonly diagnosed cancer
capable of regenerating a tumor. The CSC concept is very helpful in explaining a variety of biological and clinical observations. For example, even though there are often genetic variations among the cancer cells within the same patient, 7, 8 the large majority of genetic changes are maintained among them, 9 suggesting that most tumors may be originated from one or a few CSCs. After initial shrinkage of tumors through chemotherapy or radiotherapy, chemo-resistant or radioresistant tumors almost inevitably appear sometime later on, suggesting that there is a small population of cells likely resistant to most of current therapies. Therefore, a better understanding of the biology of CSC will uncover new strategies to diagnose tumors earlier, treat them more efficaciously, and prevent them from relapses.
It was noted by Otto Warburg nearly a century ago that tumors showed abnormal features of energy metabolism. 10 In the past decade or so, cancer metabolism has attracted renewed interests due to the development of novel biochemical and molecular biological tools and becomes one of the emerging hallmarks of all cancers. 11, 12 Cancer cells are under constant metabolic stress due to their rapid proliferation and often residing in a poorly regulated microenvironment with aberrant blood vesicles. 12 One of the key regulators of metabolic stress is AMP-activated protein kinase (AMPK), which coordinates a variety of cellular pathways to balance the energy and nutrient homeostasis. 13, 14 Here, we investigated the metabolic properties of cancer stem cells in human colorectal cancers (CRC-CSCs). We first established 6 patient-derived xenograft (PDX) colorectal cancer models using surgically removed human colorectal tumors. We then isolated CRCCSCs based on their higher aldehyde dehydrogenase (ALDH) activities using fluorescent-activated cell sorting (FACS). We showed that CRC-CSCs express higher level of antioxidant genes and contain less reactive oxygen species (ROS). The CRC-CSCs also possess more mitochondria and higher levels of ATP. Furthermore, we demonstrated that CRC-CSCs manifested higher AMPK activity and inhibition of AMPK preferentially kills the CRC-CSCs, suggesting that targeting AMPK may be an effective way to eradicate CRC-CSCs, thus preventing the relapse of CRCs. Assays were done as recommended by the manufacturer.
| MATERIALS AND METHODS

| Quantitation of cellular ATP
Cellular ATP was measured using the ATP Determination Kit (ThermoFisher, A22066). 1000 to 5000 ALDH-sorted cells were used for ATP measurement as recommended by the manufacturer. A Perkin Elmer Victor plate reader was used to measure the luminescence.
3 | RESULTS
| Isolation and validation of cancer stem cells in human colorectal tumors
In order to isolate CRC-CSCs, we first purchased a panel of human colorectal tumor samples from Asterand Bioscience. We implanted small pieces of tumors into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice within 24-48 hours after the surgery ( Figure 1A) . Within a year, we successively established 6 PDX CRC lines, which are designated as CRC#1 to CRC#6 ( Table 1) .
The surgeries for all 6 CRC patients, 2 males and 4 females, were Most studies isolated CRC-CSC using FACS based on either the expression of cell surface proteins, for example CD133 and CD44, or ALDH activity. 17, 18 We have sorted PDX CRC cells using FACS based on higher expression of CD133, CD44, and higher ALDH activity and then subcutaneously implanted them into NOD-SCID mice to test their tumorigenicity. We found that FACS-sorted CRC cells based on their ALDH activity more consistently produce tumors (Figures 1G and S1, Table 2 ). Therefore, we chose ALDH FACS as our method of isolating CRC-CSCs. A representative ALDH FACS profile of CRC cells is shown in Figure 2A . We first validated the ALDH+ CRC cells as the CRC-CSC by injecting serial diluted ALDH+ cells subcutaneously into NOD-SCID mice. As shown in Table 2 Figure S1 and Table 2 ), or produced tumors that are much smaller than that from the ALDH+ cells (CRC#1 and #6 in Table 2 ). For unknown reasons, tumors derived from ALDH+ cells of CRC#3 grew much slower than others. Therefore, we did not perform the serial dilution experiment using CRC#3.
In summary, our data demonstrated that a few of ALDH+ cells FACS sorted from most CRCs are sufficient to regenerate tumors in mice, suggesting that, in most CRCs, cancer cells with higher ALDH activity are potentially the cancer stem cells.
Another essential feature of CSCs is that, once injected into mice, they should produce a spectrum of cells similar to the pool of tumor cells that they were originally isolated from (ie, the Differentiation Test). To test the differentiation ability of the ALDH+ cells, we sorted ALDH+ cells from CRC#2 and then subcutaneously reimplanted them back into NOD-SCID mice. When the tumors grew up, we reanalyzed their ALDH profile. As seen in Figure 2B Therefore, ABCG2 could be used as a marker for differentiated cells within the colon and/or rectum. cytometer. 20 The amount of MitoSox incorporated into a cell is proportional to its ROS level. As shown in Figure 3B , ALDH+ cells indeed contain less ROS than ALDHÀ cells. In the pathway analysis, we also noticed that ALDH+ cells express considerably higher level of genes involved in mitochondrial biogenesis ( Figure 3C ). When we examined the mitochondrial protein ( Figure 3D ) as well as the mitochondrial DNA ( Figure 3E In summary, we demonstrated that CRC-CSCs contain more mitochondria and produce more ATP yet show reduced level of ROS, likely because they express higher level of antioxidant genes than the non-CRC-CSCs.
| Colorectal cancer stem cells possess unique metabolic properties
| Increased AMPK activity in CRC-CSCs promotes their survival
AMPK is often considered a low-energy sensor because it is robustly activated by the binding of AMP to its regulatory subunit when more cellular ATP is converted to AMP. 13 Since we observed that (Figure 4A) , we reasoned that the AMPK activity should be much lower in the ALDH+ cells. To our surprise, when we examined the AMPK activity by monitoring the phosphorylation of the Tyrosine-172 of its catalytic subunit, which is required for its activity, 21 as well as the phosphorylation of one of its best-known targets, acetyl-CoA carboxylase (ACC) at Serine-79, 22 we found that the ALDH+ cells actually showed the highest AMPK activity ( Figure 4C ). Next, we tested whether the higher AMPK activity is important for the cell viability CSCs, we then investigated their metabolic properties. We found that CRC-CSCs contain more mitochondria and produce more cellular ATP than the non-CRC-CSCs, yet they were able to keep the amount of ROS at a lower level. The CRC-CSCs likely achieve this by upregulating many antioxidant genes. Most intriguingly, we found that CRCCSCs manifested higher AMPK activities that are very important for their viability. Consistent with our findings, Nakada and colleagues recently showed that activation of AMPK protects leukemia initiating cells and promotes leukemogenesis. 25 Together, these data suggest that AMPK inhibitors may selectively target the cancer stem cells.
Here, we uncovered 3 unique metabolic features of CRC-CSCs:
higher AMPK activity, higher mitochondria mass/activity, and lower ROS. Based on existing evidence, it is very likely that the higher AMPK activity contributes to the increased mitochondrial mass/activity and lower ROS in the CRC-CSCs. For example, using primary mouse muscle cells and PGC1a genetic knockout mice, Spiegelman and colleagues demonstrate that deletion of PGC1a almost completely abolished the positive effects of AMPK on mitochondrial biogenesis and function. 26 Intriguingly, in our gene expression analysis, we found that PGC1a, but not PGC1b, is robustly upregulated in ALDH+ cells in all 3 CRC lines ( Figure S2 ). Therefore, it is possible that under the metabolically stressed microenvironment, CRC-CSCs activate AMPK, which then induces the expression of PGC1a and then promotes mitochondrial biogenesis. Increased mitochondrial mass/activity would provide CRC-CSCs with ample nutrients and energy for their proliferation. 11, 14 In addition, AMPK also plays an important role in attenuating the cellular ROS in cancer cells.
Recently, Hay and colleagues showed that AMPK increases NADPH level by downregulating one of the major NADPH consuming pathways -fatty acid synthesis pathway. 27 NADPH is required to synthesize a variety of antioxidants, including glutathione. In addition,
Bae and colleagues showed that inactivation of AMPK in pancreatic cancer cells increased intracellular ROS, which then led to DNA damage and cell death. 28 
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